NCT05569187View on ClinicalTrials.gov

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

CompletedOBSERVATIONAL
Enrollment

76

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions
Breast Cancer
Interventions
DRUG

Ribociclib

Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year

Trial Locations (1)

01317 000

Novartis Investigative Site, São Paulo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY